BioGaia a healthcare company working with probiotics
|
|
- Peregrine Cole
- 7 years ago
- Views:
Transcription
1 1
2 BioGaia a healthcare company working with probiotics BioGaia s vision is to improve the health of people around the world by offering first class probiotic products. BioGaia s business concept is to develop, market and sell well-documented probiotic products worldwide in the form of innovative and convenient formulations 2
3 BioGaia AB Founded in employees Officies in Stockholm, Lund, Eslöv, Raleigh, Hiroshima, Shanghai Listed on the OMX Nordic Exchange in Stockholm 1998 Products in 90 markets through distributors Contract manufacturing (TwoPac AB 100% owned) Holds 400 patents in 31 families The founders Peter Rothschild och Jan Annwall 3
4 Change of focus Oral Health Dietary Supplements Infant formula Functional Foods / Dairies Animal Health
5 BioGaia s global network Partners! Pharma and Health Food companies BioGaia! Product development, product strategies, research, Quality, market support Suppliers! Contract Manufacturing Research! Pre-clinical and clinical studies in hospitals and universities BioGaia Universities and hospitals where research is conducted. Manufacturing and Production Partners selling component products Partners selling finished goods 5
6 Business model three networks Distribution partners Sales force Pharmacies Physicians Product development Innovation & IPR Product strategies Research Quality systems Marketing support Indications Clinical Research Preclinical Food supplements Production Probiotic cultures 6
7 Distribution partner network Local distributors with medical representatives who promote to health professionals Dietary supplement BioGaia BioGaia brand Sales through Pharmacies 7
8 Bran Brand Branding for Health professionals Sold in 55 countries 61% of sales 2014 of finished products (incl. co-branding) Build value, less dependence on distributors and patents 8
9 Competition Strategy Engaged and competent personnel challenging existing solutions Clinical trials of high quality Attractive and unique formulations and packaging solutions Strong partner support 9
10 Clinical trials supporting the use of BioGaia Probiotics Lactobacillus reuteri Protectis, Prodentis and Gastrus 137 completed clinical trials in individuals 97 randomised, double-blind / blind, placebo-controlled studies in subjects 41 open studies in subjects 45 studies in 0-3y in subjects 108 scientific articles and 9 doctoral theses
11 Efficient BioGaia probiotics Functional gastrointestinal disorders Colic Regurgitation Constipation Functional abdominal pain Acute gastroenteritis Support of gastrointestinal health Antibiotic-associated side-effects Hp-infection Eradication treatment associated side-effects Gingivitis Periodontitis 11
12 Colic studies with L. reuteri Protectis Chau (2014) Szajewska (2013) L. reuteri (n = 24) Placebo (n = 28) Placebo (n=40) L. reuteri Protectis (n=40) Median duration of crying and fussing (min/day) P=0.032 P=0.018 P=0.045 P=0.804 Day 0 Day 7 Day 14 Day 21 Median crying time per day (minutes) P< P< P< P=0.002 Day 0 Day 7 Day 14 Day 21 Day 28* Savino (2010) Savino (2007) Placebo (n=21) L. reuteri Protectis (n=25) Simethicone (n=42) L. reuteri Protectis (n=41) Median crying time per day (minutes) P=0.022 Day 0 Day 7 Day 14 Day 21 Median crying time per day (minutes) P=0.005 P<0.001 P<0.001 P<0.001 Day 0 Day 7 Day 14 Day 21 Day 28 Reduction in median crying time after 21 days! Szajewska: 69% reduction with L. reuteri Protectis compared to 47% with placebo! Savino: 90% reduction with L. reuteri Protectis compared to 70% with placebo! Savino: 62% reduction with L. reuteri Protectis compared to 22% with simethicone! Chau: 54% reductiong with L. reuteri Protectis compared to 16% with placebo * Follow-up 1 week after termination of intervention
13 Cimperman et al, % reduction in diarrhoea incidence with L. reuteri Protectis compared to placebo Adults in hospital given a course of antibiotics were supplemented with L. reuteri Protectis or placebo for 4 weeks L. reuteri Protectis reduced incidence of diarrhoea by 84% compared to placebo 13
14 L. reuteri Protectis effective in constipated adults 6 p=0.023 Bowel movements per week (mean) Placebo (n=20) L. reuteri Protectis (n=20) 0 Week 0 Week 4
15 Prevention? 15
16 Gutierrez - Diarrhea in Preschool Children and L. reuteri Protectis L. reuteri Protectis (n=168) Placebo (n=168) 16
17 Study outcomes confirm previous results Reduced number of days: Gutierrez, 2014 (n=336) Weizman, 2005 (n=128) Agustina, 2012 (n=250) with diarrhoea with antibiotic use with fever NA absent from day care NA with respiratory tract infection NS NS 17
18 Indrio - Act and not React: Prophylactic use of L. reuteri Protectis in the Prevention of Colic, Regurgitation and Functional Constipation L. reuteri Protectis (n=238) Placebo (n=230) 18
19 Conclusions! Preventive use of L. reuteri Protectis in healthy newborns reduces onset of colic, regurgitation and constipation! Preventive use of L. reuteri Protectis reduces direct costs for both family and community! Preventive use of L. reuteri Protectis is proven to be valuable for both infants, parents and the society Indrio
20 Attractive and unique formulations and packaging solutions 20
21 BioGaia current products ProTectis ProDentis Gastrus Digestive Health Oral Health Stomach Health BioGaia BioGaia BioGaia BioGaia Baby Baby Junior Baby/Junior ProTectis Drops ProTectis D3 Drops ProTectis Tablets ProTectis ORS BioGaia ProTectis Tablets BioGaia ProDentis Drops BioGaia ProDentis Lozenges 1 BioGaia Gastrus Tablets
22 BioGaia partner support Clinical trials Marketing and PR support BioGaia Academy Workshops Participation in medical congresses Speakers at symposiums Education of sales representatives Social media Customer support 24/7/365 22
23 Competitors Culture suppliers Chr Hansen DuPont (Danisco) Institut Rosell Lallemand (France) Probiotic strains Valio (Finland) Probi (Sweden) Functional Foods Danone Yakult Pharma Merck (Germany) Novartis Sanofi Aventis Ferrosan (Pfizer) Bayer (USA) Other P&G Local competitors 23
24 Cooperation with Nestlé Agreement 2008 (Infant formula) Agreement 2012 (EUR 50.8 million) Drops in Mexico, U.S and UK Powder formula for children above the age of one (Royalty agreement 2013, launch end of 2014) Extended collaboration (Royalty SEK 92.0 million over three years from q2 2014) (New segment) Other ongoing development projects 24
25 Sales development 5 years Average growth: 14% Sales % % -8% +9% % Sales ) ) 1) Excluding licence revenue from Nestlé of 356 MSEK / 95,4 MSEK 25
26 Sales per geographical market 2014 Europe 67% (69) USA and Canada 8% (7) Asia 10% (13) Rest of world 15% (11) 26
27 Income statement 2014/2013 Excluding Excl Licence rev. currency effect: Net sales Paediatrics 313,7 313,7 238,6 31% 27% Net sales Adult Health 69,5 69,5 75,6-8% -12% Net sales other 3,2 3,2 1,7 Licence revenue 95,4 - - Total sales 481,8 386,4 315,9 22% 18% Cost of goods sold -131,3-131,3-101,7 Gross profit 350,5 255,1 214,2 19% Gross margin 73% 66% 68% Operating expenses BioGaia -154,7-154,7-134,3 15% Operating expenses IBT -6,6-6,6 - Exchange gain/loss on operation 7,7 7,7 1,8 Operating profit 196,9 101,5 81,7 24% 13% 1) Operating margin 41% 26% 26% Operating margin excl IBT 42% 28% 26% Exchange gain/loss on forward exchange contracts -6,6-6,6-2,9 Interest income 2,2 2,2 5,0 Profit before tax 192,5 97,1 83,8 16% Profit margin 40% 25% 27% Tax -44,5-23,5-19,6 Profit after tax 148,0 73,6 64,2 15% 1) 21 % excluding IBT expenses and currency effects 27
28 Balance sheets (MSEK) Dec, 31 Dec 31, Assets Intangible assets 6,1 - Tangible assets 72,8 60,3 Other financial assets 4,0 - Current assets 122,0 88,8 Cash and cash equivalents 210,7 234,3 Total assets 415,6 383,4 Equity and liabilities Equity attributable to owners of the Parent company 344,5 317,3 Non-controlling interets 0,1-0,5 Total equity 344,6 316,8 Deferred tax liability 0,2 0,1 Other provisions 3,9 - Interest-free current liabilities 66,9 66,5 Total equity and liabilities 415,6 383,4 Proposed dividend: SEK 5.00 per share 28
29 5 years development (2012 and 2014: excluding licence revenue from Nestlé) Total sales Gross profit Operating expenses (cost of goods excluded) Operating result Profit before tax *) *) 29
30 Key events 2014 Publication of study showing that colic can be prevented No significant differences in BioGaia s diabetes study New extended agreement with Nestlé Publication of study showing that it is possible to prevent common infections in children Agreement for the sale of drops in the UK and India Decision to extend production plant in Eslöv Publication of study showing that infants with colic cry less with BioGaia s drops Publication of study showing that BioGaia Protectis tablets are effective in constipated adults Investment in MetaboGen AB 30
31 First half year
32 Key events first 2015 Agreement on rights to sell drops in Vietnam and oral health tablets in Mexico Nestlé launched new product with BioGaia s probiotic Publication of study showing that Lactobacillus reuteri Prodentis is effective in patients with dental implants Publication of a Chinese study showing the efficacy of BioGaia s drops for infant colic BioGaia investigates the possibility of a separate listing for its subsidiary Infant Bacterial Therapeutics AB Publication of a study showing that Prodentis reduces Candida in elderly patients 32
33 Income statement first half year Exluding Excl. License rev. currenc y q1-q q1-q q1-q Change effect: Net sales Paediatrics 224,1 143,1 143,1 57% 41% Net sales Adult Health 42,1 36,2 36,2 16% 9% Net sales other 6,7 6,3 6,3 Licence revenue - 95,4 - Total sales 272,9 281,0 185,6 47% 34% Cost of goods sold -81,5-58,8-58,8 Gross profit 191,4 222,2 126,8 51% Gross margin 70% 79% 68% Operating expenses BioGaia -87,7-72,9-72,9 20% Operating expenses IBT -9,7-3,1-3,1 Exchange gain/loss on operation 1,0 2,5 2,5 Operating profit 95,0 148,7 53,3 78% 44% Operating margin 35% 80% 29% Opeating margin excl IBT 38% 54% 30% Exchange gain/loss on forward exchange contracts 4,2-3,2-3,2 Interest income 0,1 1,5 1,6 Profit before tax 99,3 147,0 51,7 92% Profit margin 36% 79% 28% Tax -20,4-32,6-11,6 Profit after tax 78,9 114,4 40,1 97% 33
34 Income statement rolling 12 months Excl. Lic. rev Excl q q q currency q q q Change effect: Net sales Paediatrics 382,2 256,0 256,0 49% 38% Net sales Adult Health 75,3 74,0 74,0 2% -4% Net sales other 16,2 7,9 7,9 Licence revenue - 95,4 - Total sales 473,7 433,3 337,9 40% 30% Cost of goods sold -154,0-108,9-108,9 Gross profit 319,7 324,4 229,0 40% Gross margin 67% 75% 68% Operating expenses BioGaia -169,6-137,8-137,8 23% Operating expenses IBT -13,2-3,3-3,3 Exchange gain/loss on operation 6,2 2,9 2,9 Operating profit 143,1 186,2 90,8 58% 32% Operating margin 30% 55% 27% Operating margin excl IBT 33% 44% 28% Exchange gain/loss on forward exchange contracts 0,8-4,5-4,5 Interest income 0,8 3,7 3,7 Profit before tax 144,7 185,4 90,0 61% Profit margin 31% 43% 27% Tax -32,3-41,3-20,3 Profit after tax 112,4 144,1 69,7 61% 34
35 Balance sheet (MSEK) June, 30 Dec 31, Assets Intangible assets 13,8 6,1 Tangible assets 79,4 72,8 Shares 4,0 4,0 Current assets 142,1 122,0 Cash and cash equivalents 202,8 210,7 Total assets 442,1 415,6 Equity and liabilities Equity attributable to owners of the Parent company 353,0 344,5 Non-controlling interets 0,1 0,1 Total equity 353,1 344,6 Deferred tax liability 0,2 0,2 Other provisions 3,9 3,9 Interest-free current liabilities 84,9 66,9 Total equity and liabilities 442,1 415,6 35
36 Sales per business unit first half year and rolling 12 months Q1-q2 Change Change Jul 14- Jul 13- Change Change q1-q ) % % 1) Jun 15 Jun 14 2) % % 1) Pediatrics 224,1 143,1 57% 42% 382,2 256,1 49% 38% Adult health 42,1 36,2 16% 9% 75,3 74,0 2% -4% Other 6,7 6,3 16,2 7,9 Total sales 272,9 185,6 47% 34% 473,7 338,0 40% 30% 1) Excluding currency effects 2) Excluding licence revenue of SEK 95.4 million 36
37 Sales per geographical market (MSEK) (excl. Licence revenue) 12 mån 12 mån Change June 15 June 14 % Europe 284,0 231,8 23% USA and Canada 42,3 21,5 97% Asia 43,7 42,7 2% Rest of world 103,7 42,0 147% 473,7 338,0 40% Europe 60% (69) USA and Canada 9% (6) Asia 9% (13) Rest of world 22% (12) 37
38 Board of Directors 2015 Paula Zeilon Stefan Elfving Chairman David Dangoor Brit Stakston Ingrid Holmström Two new board members from 7 May 2015: Ewa Björling Anthon Jahreskog Jan Annwall 38
39 Major Shareholders 30 June, 2015 A shares B shares Share capital No. of votes Capital Votes SEK 000's 000's % % 000's 000's 1 Annwall & Rothschild Inv. AB ,7% 34,0% 2 Sebastian Jahreskog ,3% 5,2% 3 Fjärde AP-fonden ,0% 2,9% 4 Handelsbankens Fonder AB ,7% 2,6% 5 Livförsäkringsaktiebolaget Skandia ,5% 2,5% 6 David Dangoor (inkl bolag) ,3% 2,4% 7 CBNY Norges Bank ,0% 2,2% 8 Banque Pictet & CIE ,9% 2,1% 9 State Street Bank & Trust com., Boston ,3% 1,7% 10 Swedbank Robur fonder ,2% 1,6% Other shareholders ,2% 42,8% Total: % 100% Total number of shareholders 30 June, 2015: 7,191 Foreign owners: 48% of capital (35% of votes) 39
40 Probiotic supplements global market Probiotic supplements historic global sales and projections (in billions $) Probiotic supplements global sales Euromonitor International
41 Launches - Drops: Launched in 72 countries - Tablets: Launched in 58 countries - ORS: Launched in 14 countries - Oral health products: Launched in 23 countries 41
42 Growth potential existing products 3 or more products from our product line launched in only 21 countries out of 70 countries Drops per new-born (from 3% up to 434%, average 105%) Contract but not launched: UK, India, Vietnam (China, South Korea) White spots: Myanmar, Thailand, Netherlands 42
43 Present focus Japan, US, UK and India Launch of new packaging solutions during the year Development program for fermentation and freeze-drying A number of projects, studies and product developments with Nestlé IBT, separate listing, new share issue and licensing TwoPac to be GMP qualified opens some Asian markets Strategic planning for MetaboGen 43
BioGaia a healthcare company working with probiotics
BioGaia presentation March 2015 1 BioGaia a healthcare company working with probiotics BioGaia s vision is to improve the health of people around the world by offering first class probiotic products. BioGaia
More informationBioGaia a healthcare company working with probiotics
BioGaia presentation June 2014 1 BioGaia a healthcare company working with probiotics BioGaia s vision is to improve the health of people around the world by offering first class probiotic products. BioGaia
More informationBioGaia a healthcare company working with probiotics
BioGaia presentation March 2014 1 BioGaia a healthcare company working with probiotics BioGaia s vision is to improve the health of people around the world by offering first class probiotic products. BioGaia
More informationPress Release 23 August, 2007 (10 pages) BioGaia AB Interim report 1 January 30 June 2007
Press Release 23 August, 2007 (10 pages) BioGaia AB Interim report 1 January 30 June 2007 (Figures in brackets refer to the previous year) - Net sales amounted to SEK 51.2 million (41.2), an increase of
More informationFinancial information and Notes
2015 Financial information and Notes Table of contents 3 Administration report BioGaia Key events of 2015 Key events after the end of the financial year Financial performance in 2015 Research and development
More informationOur new organ. Research on. Partnership with strong local distributors ANNUAL REPORT 2013
ANNUAL REPORT 2013 Our new organ Research on Partnership with strong local distributors 9 17 26 «Probiotics are attracting widespread interest from researchers around the world, and BioGaia is superbly
More informationELEKTA AB (publ) Interim report for the three months ended July 31, 2001
ELEKTA AB (publ) Interim report for the three months ended July 31, 21 Operating profit was improved by SEK 5 M to SEK 33 M (loss: 17) and the operating margin increased to 6 percent (neg: 4). Strong order
More informationPRELIMINARY UNAUDITED RESULTS FOR THE YEAR ENDED 31 DECEMBER 2014
DENSITRON TECHNOLOGIES PLC PRELIMINARY UNAUDITED RESULTS FOR THE YEAR ENDED 31 DECEMBER 2014 Densitron Technologies plc ( Densitron or the Company or the Group ), the designer, developer and distributor
More informationInterim report April-June 2003
Interim report April-June 2003 Pre-tax profit for the second quarter amounted to SEK -34m, which is a SEK 30m improvement compared to last year (SEK -64m). Software revenue grew by 5% during the second
More informationInterim report January March 2009. May 14, 2009
Interim report January March 2009 May 14, 2009 Summary January March 2009 Operational Strong first quarter with a 19 per cent increase in revenues and an 20 per cent improvement in EBIT Strong increase
More informationH & M Hennes & Mauritz AB
Six-month report (1 Dec 31 May ) H & M Hennes & Mauritz AB Six-month report First half-year (1 December 31 May ) The H&M group s sales including VAT increased by 7 percent in local currencies during the
More informationQ4 2015. Jason Clark CEO
Q4 Jason Clark CEO Strategic View Investment in Core Regions Acquire and/or scale specialist skill > Value Resolve problem countries Services Growth, maximise product sales Strengthen Functions & Governance
More informationH & M Hennes & Mauritz AB
Nine-month report (1 Dec - 31 August ) H & M Hennes & Mauritz AB Nine-month report Nine-months (1 December 31 August ) The H&M Group s sales including VAT increased in local currencies by 15 percent during
More informationBioGaia s probiotic reduced colic in infants and improved quality of life for the family
Annual report 2012 Record number of clinical studies published BioGaia s products now in 80 countries Major partnership agreement with Nestlé BioGaia s probiotic reduced colic in infants and improved quality
More informationCash flow from operating activities 5,182 2,633 6,697. Cash flow from investing activities (4,556) (2,389) (4,389)
Tamron Co., Ltd. October 30, 2008 3rd Quarter Financial Results FY 2008 Table of Contents Financial Summary Balance Sheet Statements of Income Statements of Cash Flows Group Network Overview Business Segment
More informationAllergy Obesity Cardiovascular diseases Diabetes. Source: internal data
Specific nutrition/health needs High Low Growth/ Capital building Babies/ Toddlers Maintenance/ early prevention Adulthood Life stage Aging/ problem solving Elderly/ pathology Source: internal data size
More informationINTERIM REPORT for the period January 1 June 30, 2006
ICA AB, corporate identity number 556582-1559 INTERIM REPORT for the period January 1 June 30, 2006 Strong development for ICA Group during first half year Stockholm, August 15, 2006 Net sales during the
More informationH & M Hennes & Mauritz AB
Three-month report 2015 (1 Dec 28 Feb 2015) H & M Hennes & Mauritz AB Three-month report First quarter (1 December 28 February 2015) Well-received collections for all brands in the H&M group resulted in
More informationCegedim Half-year results 2009 September 2009
Cegedim Half-year results 2009 September 2009 1 Cegedim : Healthcare - its primary market Cegedim Founded in 1969 by Jean-Claude Labrune Jean-Claude Labrune family hold 67 % of Cegedim through FCB 849
More informationJanuary 19, 2012 Sony Corporation
January 19, 2012 Sony Corporation Sony Ericsson Reports Fourth Quarter and Full Year 2011 Results and U.S. GAAP Equity Method Results for Sony s Investment in Sony Ericsson Are Expected to Include Valuation
More informationFocus on the SAS Group 2006
Focus on the SAS Group 2006 The SAS Group s airline network and hotels Approx. 1,520 daily departures 147 destinations 217 hotels The SAS Group is the 4 th largest airline group in Europe The SAS Group
More informationH & M Hennes & Mauritz AB
Full-year report (1 Dec - 30 Nov ) H & M Hennes & Mauritz AB Full-year report Full-year (1 December 30 November ) Well-received collections for all brands in the H&M Group resulted in good sales and increased
More informationInterim report January June 2015
Interim report January June Second quarter Gross cash collections SEK 834m EBIT margin 30% Acquisition of loan portfolios SEK 665m CET1 ratio 12.58% April June, year-on-year Gross cash collections increased
More informationGUNNEBO YEAR-END RELEASE 2015
Year-End Release 2015 GUNNEBO YEAR-END RELEASE 2015 Gothenburg, February 4, 2016 The CEO s comments on the fourth quarter Order intake during the quarter was good and increased organically in all regions.
More informationFull Year Report 2005. 26 January 2006
Full Year Report 2005 26 January 2006 Important Notice This Presentation has been produced by TradeDoubler AB (the Company ) and is furnished to you solely for your information. This document contains
More informationSHARE INFORMATION SHARE TREND, THE STOCKHOLM STOCK EXCHANGE, 2003 2005 30 SHARE TURNOVER 2005 (MILLION SHARES) 6,000. London NASDAQ Stockholm 5,000
SHARE INFORMATION STOCK EXCHANGE TRADING Ericsson s Class A and Class B shares are traded on the Stockholm Stock Exchange (Stockholmsbörsen) and the Class B shares are also traded on the London Stock Exchange.
More informationFIRST QUARTER 2005. Highlights from first quarter 2005 include: Operating profit 10 MNOK (42 MNOK last year)
FIRST QUARTER 2005 Highlights from first quarter 2005 include: Revenues 599 MNOK (+1 percent relative to first quarter 2004) Operating profit 10 MNOK (42 MNOK last year) Acquisition of Orwak Group completed
More informationPRESIDENT AND CEO ERIK STRAND S COMMENTS ON POOLIA S THIRD QUARTER. Press information, November 5
PRESIDENT AND CEO ERIK STRAND S COMMENTS ON POOLIA S THIRD QUARTER Press information, November 5 Poolia AB Poolia halved its rate of losses compared with the year-earlier period. The improved operating
More informationThe Castellum Share. of the company s own shares
The Castellum Share Dividend The Board proposes a dividend of SEK 6.5 per share for the financial year 21, corresponding to a yield of 6.% on the share price at the end of the year. The proposed dividend
More informationH1 2015 Audio webcast RESULTS PRESENTATION. July 30, 2015
H1 2015 Audio webcast RESULTS PRESENTATION July 30, 2015 DISCLOSURE This presentation contains no confidential material and may include publicly available market information which has not been independently
More informationGroup sales stable on a currency-neutral basis Results significantly impacted by negative currency effects adidas Group confirms full year guidance
For immediate release Herzogenaurach, May 6, 2014 First Quarter 2014 Results: Group sales stable on a currency-neutral basis Results significantly impacted by negative currency effects adidas Group confirms
More informationSupplementary Material on Consolidated Financial Results for the First Six Months of the Fiscal Year Ending December 31, 2015
Supplementary Material on Consolidated Financial Results for the First Six Months of the Fiscal Year Ending December 31, 2015
More informationVattenfall three-month Interim Report 2002 January - March
1 Vattenfall three-month Interim Report 2002 January - March Presentations by Lars G Josefsson, CEO and Matts Ekman, CFO May 15, 2002 2 Highlights Net sales more than doubled to SEK 28.4 billion Return
More informationNordic Waterproofing announces its initial public offering on Nasdaq Stockholm and prospectus in connection therewith
PRESS RELASE Helsingborg, Sweden, 30 May 2016 Nordic Waterproofing announces its initial public offering on Nasdaq Stockholm and prospectus in connection therewith IN WHICH THE DISTRIBUTION OR RELEASE
More informationVattenfall Q2 2013 results
Vattenfall Q2 2013 results Øystein Løseth, CEO and Ingrid Bonde, CFO Conference call for analysts and investors, 23 July 2013 Q2 Highlights Impairment charges on thermal assets and goodwill amounting to
More informationYear-end Report January December 2003
Year-end Report January December 2003 Anoto Group reported decreased sales by 13 per cent to SEK 192M (221), of which SEK 41M (96) in the fourth quarter. The decreased sales are attributable to C Technologies.
More informationThe Active Biotech Group Half-Year Accounts January June 2000
The Active Biotech Group Half-Year Accounts January June 2000 Results according to schedule, MSEK -59 (-75 previous year) Vaccine sales increase by 20% Continued positive development for Dukoral +42% Aventis
More informationConsolidated Financial Results for the First Quarter of the Fiscal Year Ending March 31, 2016 (Japan GAAP)
Consolidated Financial Results for the First Quarter of the Fiscal Year Ending March 31, 2016 (Japan GAAP) Name of Listed Company: Yokogawa Electric Corporation (the Company herein) Stock Exchanges Where
More informationQuarterly Report 1/2004
Quarterly Report 1/2004 Operating revenues increased in 1 th quarter to NOK 1407.0 mill. Operating profit decreased to NOK 5.4 mill. The operations of the Moelven Timber Group have been affected by the
More informationConsolidated Financial Results for the First Two Quarters of the Fiscal Year Ending March 31, 2016 (Japan GAAP)
Consolidated Financial Results for the First Two Quarters of the Fiscal Year Ending March 31, 2016 (Japan GAAP) Name of Listed Company: Yokogawa Electric Corporation (the Company herein) Stock Exchanges
More informationThree Month Report 2010. Tampa Museum of Art, Florida
Three Month Report Tampa Museum of Art, Florida 1 JanuaryMarch in brief New accounting standards Revenue for the Group SEK 25.8 bn (3.1) Revenue in Construction SEK 23.3 bn (3.5) Down 17 percent in local
More informationInterim Report for New Wave Group AB (publ)
Interim Report for New Wave Group AB (publ) Q2 january june 2006 Profit increased by 31% Sales increased by 32 % to SEK 1 652 (1 255) M during. Thereof contributed acquired units by SEK 245 M. This gives
More informationZetaDisplay. Europe leads the way. EPaccess
EPaccess Media Sweden 22 November 213 Equity Research +46 8 463 8 analys@penser.se ZetaDisplay Europe leads the way Risk and Return Potential Return Potential Risk High High Risk Current Price 4,8 High/Low
More informationChina Pharma Holdings, Inc. Reports Second Quarter 2010 Financial Results
China Pharma Holdings, Inc. Reports Second Quarter 2010 Financial Results HAIKOU CITY, China, August 10, 2010 China Pharma Holdings, Inc. (NYSE AMEX: CPHI) ( China Pharma or the Company ), a leading fully
More informationCellaVision, April 29, 2010. Yvonne Mårtensson, CEO
CellaVision, April 29, 2010 Yvonne Mårtensson, CEO Introduction CellaVision is world leader in a market with large potential, offering automated digital cell morphology The hematology analysis market comprises
More informationInterim Report First Quarter 2011 Stockholm April 20, 2011
Interim Report First Quarter 2011 Stockholm April 20, 2011 Summary of Q1 2011 Good volume growth, revenues up 10% and 17% adjusted for currency Negative impact from FX and full effect of price cuts in
More informationInterim Report for the period 1 January 31 March 2015
Interim Report for the period 1 January 31 March 2015 ALL FIGURES IN THIS REPORT ARE EXPRESSED IN SEK, UNLESS STATED OTHERWISE. FIGURES IN PARENTHESES REFER TO THE CORRESPONDING FIGURES FOR THE PREVIOUS
More informationH & M HENNES & MAURITZ AB FULL-YEAR REPORT
H & M HENNES & MAURITZ AB FULL-YEAR REPORT 1 December 2010 30 November 2011 FULL-YEAR The H&M Group s sales including VAT increased in local currencies by 8 percent during the financial year. Sales in
More informationConsolidated Financial Results for the First Three Quarters of the Fiscal Year Ending March 31, 2016 (Japan GAAP)
Consolidated Financial Results for the First Three Quarters of the Fiscal Year Ending March 31, 2016 (Japan GAAP) Name of Listed Company: Yokogawa Electric Corporation (the Company herein) Stock Exchanges
More informationJuly September 2013. July September 2014
Interim Report Interim Report Sales in the quarter increased to SEK 225.1 (216.9) million. In local currencies the decrease was 1.1 per cent. Operating profit for the quarter was SEK 12.9 (5.7) million.
More informationFINANCIAL RESULTS FOR THE PERIOD 1 JANUARY 31 MARCH 2003
FINANCIAL RESULTS FOR THE PERIOD 1 JANUARY 31 MARCH 2003 The consolidated income after financial items amounted to SEK 75.3 (3.3) million for the period, including capital gain of SEK 90.6 (30.8) million.
More informationInterim report January-March 2016
Interim report January-March 2016 The operating income was SEK 666 million (677) and the organic growth was - 2% The operating profit was SEK 23 million (34), giving an operating margin of 3.5% (5.1) The
More information1H15 Results Presentation
1H15 Results Presentation 25 February 2015 Geoffrey Babidge Managing Director & CEO 1 1H15 Result Highlights 38% revenue growth Strong Australia result UK and China initiatives gaining traction Total Revenue
More informationProbiotics for the Treatment of Adult Gastrointestinal Disorders
Probiotics for the Treatment of Adult Gastrointestinal Disorders Darren M. Brenner, M.D. Division of Gastroenterology Northwestern University, Feinberg School of Medicine Chicago, Illinois What are Probiotics?
More informationOrc Software AB Interim report January 1 March 31, 2005
Orc Software AB Interim report January 1 March 31, 2005 Revenue for January-March 2005 increased by 2 percent compared to the equivalent period in the previous year and amounted to SEK 66 (65) million.
More informationAbbott Nutrition. Attractive Profile and Compelling Growth Opportunities
Attractive Profile and Compelling Growth Opportunities Forward-Looking Statement Some statements in this presentation may be forward-looking statements for purposes of the Private Securities Litigation
More information2 ND QUARTER 2016 RESULTS ANNOUNCEMENT
2 ND QUARTER 2016 RESULTS ANNOUNCEMENT TOMRA SYSTEMS ASA 2 nd Quarter Results 19.07.2016 HIGHLIGHTS FROM THE QUARTER Revenues Gross margin Operating expenses EBITA Cashflow TOMRA Collection TOMRA Sorting
More informationInterim report January March 2009
14 May, 2009 Interim report January March 2009 STRONG FIRST QUARTER EBIT INCREASED BY 20 PER CENT Revenues increased by 19 per cent to SEK 744 M (626). EBIT increased by 20 per cent to SEK 57 M (48) and
More informationInterim report ICA AB. January 1 June 30, 2009
Interim report ICA AB January 1 June 30, 2009 Interim report Stockholm, Sweden, August 19, 2009 Increased sales and improved operating income excluding capital gains and impairments Second quarter Net
More informationInterim report January 1 March 31, 2014
Odd Molly International AB (publ) Stockholm, Sweden, April 29, 2014 Interim report January 1 March 31, 2014 More stores and new sales organization January 1 March 31, 2014 Net sales amounted to SEK 82.8
More informationLong-term industrial developer of listed Nordic companies Full year 2010 Industrivärden, February 9, 2011
Long-term industrial developer of listed Nordic companies Full year 2010 Industrivärden, February 9, 2011 Pres_KV410 Nr 1 Long-term industrial developer of listed Nordic companies Ericsson Volvo SSAB Sandvik
More informationBROSTRÖM AB (publ) Reg No 556005-1467
Broström is one of the leading logistics companies for the oil and chemical industry, focusing on industrial product and chemical tanker shipping and marine services. Broström is based all over the world
More informationQ4 2003. Outlook. Getinge Group Financial Statement 2003
Getinge Group Financial Statement 2003 Orders received totalled SEK 9,153.8 million (8,772.9) Net sales rose to SEK 9,160.2 million (8,640.1) Profit before tax climbed by 25 % to SEK 1,095.4 million (875.6)
More informationNet sales increased with 16% to SEK 76.1 m (65.6). Net sales for the last four quarters totalled SEK 255.0 m (306.6)
HMS Networks AB (publ) Interim report January-March 2010 First quarter 2010 Net sales increased with 16% to SEK 76.1 m (65.6). Net sales for the last four quarters totalled SEK 255.0 m (306.6) Operating
More informationFinancial Results for the First Quarter Ended June 30, 2014
July 28, 2014 Company name : Nissan Motor Co., Ltd. Code no : 7201 (URL http://www.nissan-global.com/en/ir/) Representative : Carlos Ghosn, President Contact person : Joji
More informationScania Interim Report, January-September 2011
21 October 2011 Scania Interim Report, January-September 2011 Summary of the first nine months of 2011 Operating income rose to SEK 9,657 m. (9,021), and earnings per share rose to SEK 9.11 (7.63) Net
More informationLong-term industrial developer of listed Nordic companies Full year 2012 Industrivärden, February 6, 2012
Long-term industrial developer of listed Nordic companies Full year 212 Industrivärden, February 6, 212 KV412_eng Nr 1 Long-term industrial developer of listed Nordic companies Ericsson Volvo SSAB Sandvik
More informationFull year results. March 2012
2 0 1 1 Full year results March 2012 1 DISCLAIMER Safe Harbour Statement This presentation contains forward-looking statements (made pursuant to the safe harbour provisions of the Private Securities Litigation
More informationInterim Report January 1 September 30, 2007
Press Release, October 24, 2007 Interim Report January 1 September 30, 2007 Third Quarter Net sales increased by 9 percent to SEK 183.8 (168.6) million. Currency-adjusted growth was 11 percent. Software
More informationInterim report. January-March 2015. President s comments. The first quarter
Interim report January-March The first quarter > > Net sales increased by 20 percent during the first quarter to SEK 1,354 M (1,129). In local currencies, net sales increased by 2 percent > > Operating
More informationGeneral Motors Company Q2 2013 Results
General Motors Company 2013 Results July 25, 2013 Forward Looking Statements In this presentation and in related comments by our management, our use of the words expect, anticipate, possible, potential,
More informationHowellust
Year-end report 1 January 31 December 2013 Net sales rose to SEK 479.4 M (433.8), up approximately 12%.* Order bookings totalled SEK 460.5 M (447.6), up about 4%.* Operating profit amounted to SEK 48.0
More informationPYROSEQUENCING AB. Interim report January - September 2003
1 PYROSEQUENCING AB Interim report January - September 2003 Uppsala, Sweden, October 23, 2003. Pyrosequencing AB (Stockholm: PYRO A) today reported results for the first nine months 2003. Highlights (Figures
More informationCapio intends to be listed on the Nasdaq Stockholm Stock Exchange
NOT FOR DISTRIBUTION OR RELEASE, DIRECTLY OR INDIRECTLY, TO U.S. NEWS WIRE SERVICES OR PUBLICATION IN OR INTO THE UNITED STATES, CANADA, AUSTRALIA, JAPAN, NEW ZEALAND, SOUTH AFRICA, HONG KONG, SINGAPORE
More informationHealth Care Worldwide. Citi - European Credit Conference September 24, 2015 - London
Health Care Worldwide Citi - European Credit Conference September 24, 2015 - London Safe Harbor Statement This presentation contains forward-looking statements that are subject to various risks and uncertainties.
More informationXebec Adsorption Inc.
Condensed Interim Consolidated Financial Statements (Unaudited) The Condensed Interim Consolidated Financial Statements which are included in this Report have not been subject to a review by the Company
More informationFinancial Results. siemens.com
s Financial Results Fourth Quarter and Fiscal 2015 siemens.com Key figures (in millions of, except where otherwise stated) Volume Q4 % Change Fiscal Year % Change FY 2015 FY 2014 Actual Comp. 1 2015 2014
More informationIncreasing market share in a receding market
Interim report for the first quarter of the financial year 2008/2009 Increasing market share in a receding market First quarter (September November 2008) KappAhl s net sales (excluding VAT) for the period
More informationINTERIM REPORT, 1 January - 30 June 2003
PRESS RELEASE, 9 July INTERIM REPORT, 1 January - 30 June In May, Medivir reached a licensing agreement on MIV-210 with GlaxoSmithKline; EUR 6 m was received upon signing and up to EUR 86 m on the achievement
More informationConsolidated balance sheet
83 Consolidated balance sheet December 31 Non-current assets Goodwill 14 675.1 978.4 Other intangible assets 14 317.4 303.8 Property, plant, and equipment 15 530.7 492.0 Investment in associates 16 2.5
More informationINTERIM REPORT Q3 2013
INTERIM REPORT Q3 2013 July - September 2013 Betting turnover: 132,779 KEUR (159,829) Net turnover after trading fees: -173 KEUR (802) Gross margin: -0.13% (0.50) 1 Operating income: -1,105 KEUR (-34)
More informationHealth Care Worldwide
Health Care Worldwide Goldman Sachs - Leveraged Finance Healthcare Conference March 4, 2014 New York Goldman Sachs Leveraged Finance Conference, Fresenius SE & Co. KGaA Copyright, March 4, 2014 Page 1
More informationInterim report ICA AB. January 1 March 31, 2009
Interim report ICA AB January 1 March 31, 2009 Interim report Stockholm, May 6, 2009 Increased net sales and improved operating income for the ICA Group during the first quarter First quarter Net sales
More informationOrder bookings 48,719 55,565-12 12,835 14,845 Sales 48,331 56,492-14 13,166 17,076
28 January, 2002 SCANIA YEAR-END REPORT JANUARY - DECEMBER 2001 After the unsatisfactory 2001, our measures to adjust production to lower global demand, structural changes related to cab production and
More informationFOSSIL GROUP, INC. REPORTS THIRD QUARTER 2014 RESULTS. Third Quarter Net Sales Increase 10% to $894 Million; Diluted EPS Increases 24% to $1.
FOSSIL GROUP, INC. REPORTS THIRD QUARTER RESULTS Third Quarter Net Sales Increase 10% to $894 Million; Diluted EPS Increases 24% to $1.96 Updates Full Year Guidance and Provides Fourth Quarter Guidance
More informationFinancial supplement (unaudited) 2014. Zurich Insurance Group Annual Report 2014
Financial supplement (unaudited) 204 Zurich Insurance Group Annual Report 204 2 Contents Results for the year ended December 3, 204 Financial supplement (unaudited) Financial highlights (unaudited) Business
More informationYEAR-END REPORT for the period January 1 December 31, 2006
Year-end report for ICA AB January 1 - December 31, 2006 YEAR-END REPORT for the period January 1 December 31, 2006 Stockholm, February 21, 2007 Strong net income for ICA Group in 2006 despite weak fourth
More informationFINANCIAL YEAR 2005. Sales Development 2005. Breakdown of sales by regions
FINANCIAL YEAR 2005 In fiscal year 2005, the SCHWARZ PHARMA Group achieved sales of 990.6 million, marking a 4.6% increase over the previous year. The acquisition of the entire rotigotine rights in July
More informationH & M Hennes & Mauritz AB Full-year Report
H & M Hennes & Mauritz AB Full-year Report 1 December 2012 30 November 2013 FULL-YEAR The H&M Group s sales including VAT increased in local currencies by 9 percent during the financial year. Sales in
More informationFINANCIAL RESULTS Q2 2015
FINANCIAL RESULTS Q2 2015 CEO CHRISTIAN RYNNING-TØNNESEN CFO HALLVARD GRANHEIM 23 July 2015 Highlights Solid underlying results (EBITDA) - Lower Nordic prices offset by increased production and contribution
More informationRecipharm creates a global CDMO leader through SEK 1.7 billion strategic acquisitions in the US, Sweden and India
Press release 18 th April 2016 Recipharm creates a global CDMO leader through SEK 1.7 billion strategic acquisitions in the US, Sweden and India Recipharm AB (publ) ( Recipharm or the Company ) announces
More informationYear-end report. President s comments. The fourth quarter. January - December
Year-end report The fourth quarter > > Net sales increased by 17 percent during the fourth quarter to SEK 1,758 M (1,504). In local currencies, net sales increased by 7 percent > > Operating profit increased
More informationH & M Hennes & Mauritz AB
Six-month report (1 Dec 31 May ) H & M Hennes & Mauritz AB Six-month report First half-year (1 December 31 May ) Well-received collections for all brands in the H&M group resulted in good sales and increased
More informationFor personal use only
COMPUMEDICS LIMITED (ACN 006 854 897) ASX final report 30 June 2014 Lodged with the ASX under Listing Rule 4.3A Contents Results for Announcement to the Market (Appendix 4E item 2) Consolidated statement
More informationSiegfried when substance matters Semi-annual report 2008
Siegfried when substance matters Semi-annual report 2008 Key figures Continuing Operations 1 st Half-Year 2008 1 st Half-Year 2007 Difference Change in % Net sales (million CHF) 159.6 157.8 1.8 1.2 Net
More informationHealth Care Worldwide
Health Care Worldwide Barclays European High Yield and Leveraged Finance Conference October 30, 2014 London Barclays European High Yield and Leveraged Finance Conference, October 30, 2014 Copyright Page
More informationcondensed consolidated interim financial statements 2015
January march 2015 condensed consolidated interim financial statements 2015 (unaudited) contents 1. Income Statement 1 2. Statement of Comprehensive Income 2 3. Balance Sheet 3 4. Statement of Changes
More informationPRESS RELEASE DANIELI GROUP
DANIELI & C. OFFICINE MECCANICHE S.p.A. Buttrio (UD) via Nazionale n. 41 Fully paid-up share capital of euro 81,304,566 Registration Number with the Register of Companies of Udine, tax number and VAT registration
More informationadidas Group records stellar financial performance in Q3 2015 and raises full year guidance
FOR IMMEDIATE RELEASE Herzogenaurach, November 5, 2015 Nine Months 2015 Results: adidas Group records stellar financial performance in Q3 2015 and raises full year guidance Major developments in Q3 2015
More informationFinancial supplement 2013. Zurich Insurance Group Annual Report 2013
Financial supplement 2013 Zurich Insurance Group Annual Report 2013 2 Contents Results for the Year ended December 31, 2013 Financial supplement (unaudited) Financial highlights (unaudited) Business operating
More information